BHCM
AQST icon

Brevan Howard Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Brevan Howard Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,738
Closed -$438K – 2135
2025
Q4 		$438K Buy
67,738
+33,863
+100% +$211K ﹤0.01% 1176
2025
Q3 		$189K Buy
+33,875
New +$146K ﹤0.01% 1765
2024
Q2 		– Sell
-17,965
Closed -$76.5K – 1056
2024
Q1 		$76.5K Buy
+17,965
New +$59.8K ﹤0.01% 918

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brevan Howard Capital Management's AQST Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 67,738 shares — an estimated $438K sold.

Brevan Howard Capital Management first reported a position in AQST in Q1 2024 and held it in 3 quarters. The position peaked at $438K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 67,738 Aquestive Therapeutics shares in Q1 2026, an estimated $438K.
  • Brevan Howard Capital Management first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's Aquestive Therapeutics position peaked at $438K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.